Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

NCT00451997 ↗

Phase 2 Completed 10 enrolled M.D. Anderson Cancer Center Novartis · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose chemotherapy.

Timeline

Start: 2004-03
Primary completion: 2005-08
Completion: 2007-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytarabine	Small molecule	10 mg	Subcutaneous
Subject	Imatinib	Small molecule	600 mg	Oral

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Summary

Timeline

Drugs

Indications